In this video, Motley Fool health-care analyst David Williamson takes a look at Threshold's big week and the news on Friday that has shares soaring even higher. Find out what it means for investors in Threshold and competitor Celgene if MAESTRO is a success.
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.
The article Will Threshold's MAESTRO Hit the Right Note? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.